Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (29)

2024

  1. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

2023

  1. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

    HemaSphere

  2. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

    European Journal of Haematology, Vol. 111, Núm. 3, pp. 485-490

2022

  1. Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain

    Leukemia and Lymphoma

2021

  1. Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

    Leukemia Research, Vol. 109

  2. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

    Blood, Vol. 137, Núm. 14, pp. 1879-1894

2020

  1. A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial

    Cancer Medicine, Vol. 9, Núm. 7, pp. 2317-2329

  2. Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. e513-e522

2019

  1. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

  2. Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group

    Cancer, Vol. 125, Núm. 16, pp. 2810-2817

  3. Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials

    European Journal of Haematology, Vol. 102, Núm. 1, pp. 79-86

  4. Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

    Genes Chromosomes and Cancer, Vol. 58, Núm. 11, pp. 815-819

  5. The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients

    British Journal of Haematology, Vol. 186, Núm. 2, pp. 263-268

2018

  1. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 1, pp. 146-154

  2. Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia

    Leukemia and Lymphoma, Vol. 59, Núm. 5, pp. 1095-1104

2017

  1. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid

    Annals of hematology, Vol. 96, Núm. 7, pp. 1069-1075

2016

  1. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

    Leukemia & lymphoma, Vol. 57, Núm. 1, pp. 86-91

  2. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

    Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924

  3. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab

    British journal of haematology, Vol. 172, Núm. 3, pp. 428-438

2015

  1. Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia

    Leukemia and Lymphoma, Vol. 56, Núm. 10, pp. 2812-2818